61.56 USD
-1.36 (-2.16%)
Last: Feb 11, 2026, 02:17 PM
ChartMill assigns a Buy % Consensus number of 79% to ARWR. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 81.91. This target is 33.06% above the current price.
- ARWR was analyzed by 20 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about ARWR.
- In the previous month the buy percentage consensus was at a similar level.
- ARWR was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-22 | B. Riley Securities | Maintains | Buy -> Buy |
| 2026-01-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-13 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2026-01-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-01-07 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2026-01-07 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-17 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-12-11 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-09 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-01 | B of A Securities | Maintains | Buy -> Buy |
| 2025-11-26 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-20 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-11-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-19 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-19 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-11-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-13 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-02-14 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2025-02-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-02-11 | RBC Capital | Reiterate | Outperform -> Outperform |
ARROWHEAD PHARMACEUTICALS IN / ARWR FAQ
What is the price target for ARWR stock?
20 analysts have analysed ARWR and the average price target is 81.91 USD. This implies a price increase of 33.06% is expected in the next year compared to the current price of 61.56.
What is the consensus rating for ARROWHEAD PHARMACEUTICALS IN (ARWR) stock?
The consensus rating for ARROWHEAD PHARMACEUTICALS IN (ARWR) is 79 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for ARWR stock?
The number of analysts covering ARROWHEAD PHARMACEUTICALS IN (ARWR) is 20.